Ocular Therapeutix (OCUL) Posts Wider Losses And Files Shelf Registration, Is It Still Undervalued?

Earnings and Shelf Registration Put Ocular Therapeutix in Focus

Ocular Therapeutix (OCUL) is back on investors’ radar after its latest quarterly earnings and a new shelf registration filing that opens the door to potential future common stock issuance.

See our latest analysis for Ocular Therapeutix.

The recent 4.82% 1 day share price return and 20.35% 7 day share price return suggest investors are reacting to Ocular Therapeutix’s earnings and shelf registration, although the share price remains down 13.45% year to date with a mixed longer term total shareholder return record.

If these moves in Ocular Therapeutix have caught your attention, it can be useful to see what other healthcare focused AI opportunities look like through the 43 healthcare AI stocks

For Ocular Therapeutix, the share price jump has arrived alongside steady revenue, wider losses and a fresh shelf registration that points to possible dilution. Is this a business reset, or just a sharp turn in sentiment before valuation work begins?

Most Popular Narrative: 60.7% Undervalued

At a last close of $10.23 against a most followed fair value estimate of $26.00, the current pricing for Ocular Therapeutix sits well below that narrative benchmark and puts the focus firmly on what would need to go right for the story to play out.

The anticipated approval of AXPAXLI, potentially the first wet AMD product with a superiority label and longer dosing intervals (every 6 to 12 months), may allow Ocular Therapeutix to capture significant market share in a rapidly growing population of elderly patients with retinal disease, unlocking large revenue growth opportunities as the global prevalence of ophthalmic disorders increases.

Read the complete narrative.

Curious what sits behind that confidence in AXPAXLI and the fair value of $26.00. The narrative leans on rapid revenue expansion, margin repair and a rich future earnings multiple that assumes a very different profit profile to today.

Result: Fair Value of $26.00 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Ocular Therapeutix still hinges heavily on the AXPAXLI trial and regulatory outcomes, and any need for extra funding beyond 2028 could quickly challenge this upbeat narrative.

Find out about the key risks to this Ocular Therapeutix narrative.

Another View on Ocular Therapeutix Valuation

The SWS DCF model presents a very different picture for Ocular Therapeutix. At a share price of $10.23, the stock is trading around 90.9% below an estimated future cash flow value of $112.16, which indicates a very large implied upside. Does that align with your own assumptions on risk and execution?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

The mix of optimism and concern around Ocular Therapeutix may feel conflicting, so act quickly and review the details for yourself. To balance the bigger picture on both fronts, start with the 2 key rewards and 3 important warning signs

Looking For More Investment Ideas Beyond Ocular Therapeutix?

If Ocular Therapeutix has sharpened your focus on stock selection, now is the time to widen your search and compare it with other potential opportunities across the market.

• Scan for potential mispriced opportunities that combine quality and value, starting with the 49 high quality undervalued stocks.
• Target companies that may offer resilience through steadier finances by checking the solid balance sheet and fundamentals stocks screener (49 results).
• Hunt for potential future standouts that are still off many investors' radar through the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com